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 ANKİLOZAN SPONDİLİTLİ HASTALARDA ANTİ-TNF-ALFA TEDAVİ ÖNCESİ VE 
SONRASI SAKROİLİAK EKLEMLERİN MANYETİK REZONANS İLE 
GÖRÜNTÜLENMESİ 
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ÖZET
AMAÇ: Çalışmanın amacı, dirençli AS'li hastalarda, anti-TNF-alfa ilaçların etkinliğini ve güvenirliğini yanısıra, 
manyetik rezonans (MR) görüntüleme ile tedavi öncesi ve sonrası sakroiliak eklem değişiklerini tespit etmektir.
GEREÇ ve YÖNTEM: Modifiye New York tanı kriterlerine göre AS tanısı almış, 27 hasta çalışmaya dahil 
edildi. Sakroiilitis bulguları, anti-TNF-alfa tedavi öncesi ve sonrası, Gd-MR ile tespit edildi. Sekiz hastaya, 4 
haftada bir İnfliximab 4mg/kg i.v. infüzyon verildi. Diğer 19 hastaya ise Etanercept 2x25mg/hafta s.c. verildi. 
Değerlendirilen klinik ve laboratuvar parametreler; BASDAİ, BASFİ, ağrı (VAS skoru), Schöber testi, göğüs 
ekspansiyonu, C-reaktif protein (CRP), eritrosit sedimentasyon hızı (ESH).
BULGULAR: Hastaların çoğu, anti-TNF-alfa tedavilerine iyi yanıt verdi. 24.haftanın sonunda, takip edilen tüm 
parametrelerde iyileşme gözlendi. MR görüntüleme çalışmalarında, anti-TNF-alfa tedavi sonrası sadece 3 
hastanın sakroiliak eklem inflamasyonunda gerileme gözlendi. 
SONUÇ: Aktif AS'li hastalarda, 24.hafta sonunda anti-TNF-alfa ilaçları güvenilir ve etkin bulundu. BASDAİ, 
BASFİ, ağrı skorlarında belirgin düşüş gözlendi. Fakat, sakroiliak eklemin akut inflamatuvar bulgularında, MR 
görüntüleme ile herhangi bir gerileme tespit edilmedi.
Anahtar sözcükler: Ankilozan spondilit, anti-TNF-α ilaçlar, manyetik rezonans görüntüleme, sakroiliak eklem
Magnetic Resonance Imaging of the Sacroiliac Joints in Ankylosing Spondylitis Before and After 
Therapy with Anti-Tumor Necrosis Factor Alpha 
SUMMARY
OBJECTIVE: The goal of this study is to assess the changes in the sacroiliac joints (Sİ) by magnetic resonance 
imaging (MRI) in a 24-week follow-up period and to determine the efficacy and safety of anti-TNF-α therapies 
for refractory AS. 
MATERIAL and METHODS: Twenty-seven patients who met the modified New York criteria for AS were 
enrolled in this study. Activity of sacroiliitis was determined by Gd-MRI scan before and after anti-TNF-α 
treatment. Eight patients received infliximab at a dose of 4 mg/kg by intravenous infusion over 2 hours at every 4 
week. Other 19 patients were treated with 25mg subcutaneous etanercept twice weekly The total observational 
period was 24 weeks. The clinical and laboratory variables included: Bath AS Disease Activity Index (BASDAI), 
Bath AS Functional Index (BASFI), pain on a visual analog scale, Schober's index, chest expansion, C-reactive 
protein (CRP), erythrocyte sedimentation rate (ESR).
RESULTS: Most patients responded well to treatment of anti-TNF-α antagonists. At 24 weeks, there was an 
improvement in all of the following measures. Imaging studies showed decreased inflammation of the SI joints 
after 24 weeks of treatment with anti-TNF-α therapies in only 3 patients. 
CONCLUSION: The anti-TNF-α therapies was safe and effective in treating patients with active AS during 24-
week study period. The BASDAI, BASFI, VAS of pain were decreased well. But we could not determine any 
regression of acute inflammatory changes of the SI joints as depicted by MRI.
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Ankylosing spondylitis (AS), the prototype of 
spondyloarthritis, is a chronic inflammatory 
rheumatic diseases, leading to progressive spinal 
1
ankylosis and deformity . Its pathogenesis is 
2
incompletely understood . The fırst symptoms 
normally occur in the second and thırd decade of life.  
AS most offen starts with inflammation of the 
sacroiliac joints (SI) and affect mainly the axial 
3,4
skeleton . Until recently, non-steroidal anti-
inflammatory drugs (NSAIDs) and physical therapy 
were the only accepted treatment. The only disease 
modifying antirheumatic drug (DMARDs) that has 
been demonstrated to be useful for AS is sulfasalasine 
(SSZ), which has a proven beneficial effect for 
peripheral arthritis and enthesitis and nearly 
5,6
imperceptible for spondylitis . 
Tumor necrosis factor-alpha (TNF-α) has been 
determined in sacroiliac joints of patients with AS. 
TNF-α mRNA and protein have been identified in the 
sacroiliac joint (SI) biopsies of patients with active 
disease suggesting a role for this cytokine in the target 
7
organ inflammation . Over the past few years several 
placebo controlled and open trials have shown a 
dramatic response in active AS to TNF-α blocking 
8 - 1 0
agents . Studies on magnetic resonance 
imaging(MRI) of SI joints in AS indicate that MRI 
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enables early diagnosis of sacroiliitis . Dynamic MRI 
has been shown to be useful in the detection of both 
12,13
early SI joint and spinal inflammation in AS .
In this study, our aim was to determine the 
efficacy and safety of anti-TNF-α therapies for 
refractory AS and to assess the changes in the SI joints 
by MRI in a 24-week follow-up period before and after 
treatment.
MATERIAL and METHODS
Twenty-seven (18 men and 9 women) who met 
the modified New York criteria for AS and anti-TNF-
alpha naive patients were enrolled in this 24-week 
study. All patients gave written informed consent. 
Before study entry, all patients were evaluated for 
latent tuberculosis by a tuberculin test and chest 
radiographs. Despite treatment with methotrexate 
(MTX) at least 10mg/week, sulfasalazine (SSZ) 
3g/day, corticosteroid 4mg/day, nonsteroid 
antiinflammatory drugs (NSAIDs), at the time of 
enrollment, all patients had active disease. Disease 
modifying drugs, such as SSZ, MTX were not allowed 
during the study. Patients were allowed to continue 
NSAIDs and/or corticosteroids(<10mg/day 
prednisolone), provided that the dosage and schedule 
regiment were stable at least 4 weeks prior to baseline 
and troughout the study. Eight patients received 
infliximab at a median dose of 4mg/kg by intravenous 
infusion over 2 hours at every 4 week. Other 19 
patients were treated with 25mg subcutaneous 
etanercept twice weekly. The total observational 
period was 24 weeks.The clinical variables included: 
Bath AS Disease Activity İndex (BASDAI), Bath AS 
Functional Index (BASFI), pain on a visual analog 
scale The laboratory variables for activity of disease 
included:C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR). All the above variables 
(clinical and laboratory ) were evaluated at week 0, 4, 
8, 16, 24. Furhermore, a complete blood count and 
biochemical measurements were obtained at each 
patient visit.
MRI examination of the sacroiliac joints
Activity of sacroiliitis was determined by Gd-
MRI scan before and after anti-TNF-alpha treatment. 
The following sequences were used: T1 weighted spin 
echo (SE), short tau inversion recovery (STIR), T2 
weighted fast SE with fat saturation and T1 weighted 
SE with fat suppression after the intravenous 
administration of contrast medium (gadolinium 
diethylenetriaminepentate, 0.1 mmol/kg body 
weight). Inflammation was scored for each sacroiliac 
joint in the joint space, subchondral bone, bone 
marrow, ligaments, and joint capsule. Inflammation 
was defined as a low signal intensity on T1, with 
enhancement after gadolinium administration, and/or 
high signal intensity on STIR, and/or T2 fast SE. 
Inflammation in ligaments was defined as areas of low 
signal intensity running through high signal intensity 
tissue on T1, which reflects interosseous ligaments 
crossing juxtaarticular fatty tissue. Structural changes 
(erosions, sclerosis, ankylosis) were scored in joint 
space, subchondral bone, and bone marrow. 
Statistical analysis
SPSS was used to analyze the data. Data were 
summarized as frequency and percentages. t-test was 
used for comparison of numerical variables. The level 
of significance was accepted as p<0.05.
RESULTS
The mean age was 46,3± 12,3 years (range 20-
70) and mean disease duration was 12,1±3,4 years 
(range:5-20). Ten patients were HLA-B27 positive. 
Nine patients had peripheric arthritis and 8 patients 
had enthesitis. Five patients had a prior history of 
anterior uveitis. All 27 patients responded well to 
treatment of anti TNF-alpha agents. At 24 weeks, there 
was an improvement in all of the following measures: 
BASDAI, BASFI, patient global assessment, 
physician global assessment, pain scores. For 
BASDAI, there was a reduction from 6,3 at baseline to 
3,5 at 24 weeks. ESR and CRP showed significant 
improvement at 6 weeks and were maintained to the 24 
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 Characteristic                                                         Patients(n=27) 
Age/years/mean                                                             46.3±12.3 
Disease duration/years                                                   12.1±3.4                      
Sex/male                                                                        18(66.6%) 
History of anterior üveitis                                              5(18.5%) 
Peripheric arthritis                                                          9(33.3%) 
Enthesitis                                                                         8(29.6%) 
HLA B-27 positivity                                                       10(37%) 
 
 
Table 1. Demographic data of 27 patients with AS.
week assessment point. The mean baseline scores for 
inflammatory markers in the peripheral blood were 
53,4mm/h for ESR(reference range 0-15), 3,5mg/dl 
for CRP(reference range<0,5mg/dl). At week 24, 
there was an improvement in inflammatory 
markers(median ESR were 16,2mm/h, median CRP 
were 0,4 mg/dl respectively). Also peripheral arthritis, 
enthesitis and spinal symptoms improved. There was a 
improvement in Schober's index and chest expansion 
at 24 weeks, but there was not statistically significant. 
Imaging studies before and after 24 weeks of treatment 
with anti-TNF-α was performed in 22 patients. Active 
inflammation depicted by MRI was seen in 20 patient. 
Among these patients, 12 had bilaterally sacroiliitis. 
Inflammation of the subchondral region and the bone 
marrow was the most frequently observed finding. 
Only one patient had inflammation excluding the bone 
marrow and subchondral bone. The pathological 
findings were mostly scored as grade 2, representing 
moderate involvement. Structural changes was seen in 
all 22 patients. Similarly to inflammation, about one 
half of the patients with structural changes showed 
these changes bilaterally. Furthermore, after 24 weeks 
of continuous treatment of 22 patients with AS with 
anti-TNF-α agents there was a slight but not 
significant decrease of the mean score for active 
inflammatory lesions in the SI joints. MRI showed 
decreased inflammation of the SI joints  in only 3 
patients. Among  these 3 patients,  2 were women and 
all of them has been treated with etanercept. All of 
these 3 patients had  positivity for HLA-B27 antigen. 
Also no difference in chronic changes was found 
among the patients with AS after 24 weeks of 
treatment with anti-TNF-α drugs. Despite clinically 
and laboratory improvement there are no showed 
regression of inflammatory findings of sacroiliac 
joints.  During follow-up of the treatment, 3 patients 
developed headache, one patient developed allergic 
reaction during the infusion. Infections was developed 
in 4 patients (one pneumonia, 3 urinary tract 
infection). No patient developed ANA or anti-dsDNA 
antibodies. No clinical events occured to suggest a 
lupus-like illness in any patient.
DISCUSSION
Our study shows that treatment of patients with 
active AS  with anti-TNF-α agents are not associated 
with a significant reduction of active inflammatory 
changes of the sacroiliac joints as depicted by MRI. 
Active inflammatory findings as bone marrow 
oedema and enhancement of the contrast agent was 
persisted after 24 week follow period. Only 3 patients 
had regression of acute inflammatory findings 
depicted by MRI. During the study, no progression 
occurred of chronic changes of the SI joints as 
depicted by MRI. Results of studies of the influence of 
anti-TNF-α treatments on spinal and sacroiliac joints 
inflammation in AS are promising. Rudwaleit et all. 
showed that etanercept treatment in patients with 
active AS and  uSpA leads to regression of active 
inflammatory lesions of the spine as depicted by 
14
MRI . In this study, there was only a trend for a 
decrease of active inflammatory lesions of the SI 
joints. Braun et all. showed clinical improvement in 
patients with active AS who were treated with 
infliximab and  significant regression of spinal 
15
inflammation  by using the MRI activity scores . 
Won-Hee Jee et all showed that synovial enhancement 
at MR imaging could correlate disease activity as 
measured by laboratory inflammatory markers in 
16
ankylosing spondylitis . 
By investigating results of sacroiliac biopsies 
demonstrated that there is a fair correlation between 
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Follow-
up 
 
BASDAI 
  0-10cm 
  median 
 
BASFI 
 0-10cm 
 median 
 
ESR 
 mm/h 
 median 
 
CRP 
 mg/dl 
 median 
 
Pain  
 0-10cm 
 median 
 
Schober 
    cm 
 median 
 
   Chest 
expansion 
     cm 
  median 
 
Baseline 
 
6.3*±0.93 
 
6.5*±0.97 
 
53.4*±2.12 
 
3.5*±0.74 
 
7.2*±0.80 
 
2.1±0.89 
 
3.1±0.75 
 
8.week 
 
3.0±1.03 
 
2.5±0,58 
 
17.4±1.97 
 
0.6±0.93 
 
3.1±1.01 
 
3.5±0.74 
 
4.0±1.29 
 
24.week 
 
3.5*±0.74 
 
2.8*±1.26 
 
16.2*±1.93 
 
0.4*±0.57 
 
3.4*±0.77 
 
4.1±1.27 
 
5.2±1.33 
 
Table 2. Clinical and laboratory follow-up of patients with AS during anti-TNF-α  treatment.
*t-test was performed, p<0.05 was accepted as significance
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MRI activity and histologic scores of inflammation . 
Thus, we are not surprised that infliximab and 
etanercept ,  a  potent  inhibitors  of  major 
proinflammatory cytokine TNF-α, are able to reduce 
spinal inflammation, especially because spinal 
inflammation in AS is associated with new blood 
vessel formation. This may be a factor that most likely 
contributes to the enhancement seen after application 
of contrast agent. Therefore,  improvement in spinal 
inflammation induced by anti-TNF-α therapies will 
lead to a reduction of blood vessels at inflamed sites. 
These data suggest that regression of bone marrow 
edema appears to be a sensitive sign of improvement 
18
of spinal inflammation in AS .In our study despite of 
clinically and laboratory improvement of patients 
there are not radiologically regression on MRI. Active 
inflammatory lesions of the SI joints showed only 
moderate and non-significant regression of such 
lesions upon treatment with anti-TNF-α agents. In 
only 3 patients noted some decrease of active 
inflammatory lesions after 24 weeks. Thus, one 
possible explanation is that the scoring method 
applied for the SI joints is not sufficiently sensitive to 
change. Whether semiaxial planes in addition to the 
conventional semicoronal planes of the SI joints 
would have added further information on the change in 
the SI joints is unknown, but unlikely. Further studies 
on MRI examination of the SI joints will provide more 
information on this issue.
The relatively small size of the present study 
group limits our ability to draw extensive conclusions. 
According to our data, anti-TNF-α therapies has 
strong clinical efficacy on many aspects of active AS 
and leads to significant regression of active 
inflammatory  markers. But we could not determine 
any regression of acute inflammatory  changes of the 
SI joints as depicted by MRI. Some effects on the SI 
joints were also detected, but this was not statistically 
significant, possibly indicating that the scoring 
method used lacks sensitivity to change. However, 
further clinical studies are needed to shows the 
efficacy of anti-TNF-α agents on active inflammatory 
changes of sacroiliac joints.
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                                                            MRI findings(R/L) 
                             Active inflammation(R/L)                       Chronic changes(R/L) 
Pts             Before treatment   After treatment        Before treatment         After  treatment
 
1                         +/+                      +/+                              +/+                        +/+    
2                          -/+                       -/+                              +/+                        +/+ 
3                         +/+                      +/+                               -/+                         -/+ 
4                         +/+                       -/-                               +/-                         +/- 
5                         +/+                      +/+                              +/+                        +/+ 
6                          -/+                       -/+                              +/+                        +/+ 
7                          -/+                       -/+                               -/+                         -/+                                  
8                         +/+                       -/-                               +/+                        +/+ 
9                         +/+                      +/+                              +/+                        +/+ 
10                        -/+                       -/+                              +/-                         +/-  
11                       +/+                      +/+                              +/+                        +/+ 
12                       +/+                       -/-                                -/+                         -/+                       
13                        -/+                       -/+                               -/+                         -/+ 
14                       +/+                      +/+                               +/+                       +/+ 
15                        +/-                      +/-                                 -/+                        -/+             
16                        -/+                       -/+                               +/+                       +/+ 
17                        -/+                       -/+                               +/+                       +/+    
18                        +/+                     +/+                               +/+                        +/+ 
19                        +/+                     +/+                                -/+                         -/+ 
20                         -/-                      -/-                                  -/+                         -/+ 
21                        +/+                     +/+                                -/+                         -/+ 
22                         -/-                       -/-                                +/-                          +/- 
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